{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:58:39Z","timestamp":1790841519987,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurol.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T07:36:19Z","timestamp":1672385779000},"page":"35-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of Charcot-Marie-Tooth neuropathies"],"prefix":"10.1016","volume":"179","author":[{"given":"S.","family":"Beloribi-Djefaflia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0560","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/jamaneurol.2016.0171","article-title":"Phenotypic variability of childhood Charcot-Marie-Tooth disease","volume":"73","author":"Cornett","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.11.006_bib0565","article-title":"In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; Clinical Characteristics of Charcot-Marie-Tooth (CMT) Hereditary Neuropathy","author":"Bird","year":"1993","journal-title":"Gene Rev"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0570","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ejhg.2009.31","article-title":"Charcot-Marie-Tooth disease","volume":"17","author":"Kinga Szigeti","year":"2006","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"10.1016\/j.neurol.2022.11.006_bib0575","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00415-017-8474-3","article-title":"Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review","volume":"264","author":"Berciano","year":"2017","journal-title":"J. Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/NMM:8:1-2:3","article-title":"Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease","volume":"8","author":"Pareyson","year":"2006","journal-title":"NeuroMolecular Med"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000472166","article-title":"Estimation of the mutation frequencies in charcot-marie-tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study","volume":"4","author":"Van Broeckhoven","year":"1996","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0590","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.22166","article-title":"Charcot-marie-tooth disease subtypes and genetic testing strategies","volume":"69","author":"Saporta","year":"2011","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2022.11.006_bib0595","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/brainsci11111447","article-title":"Challenges in treating charcot-marie-tooth disease and related neuropathies: current management and future perspectives","volume":"29","author":"Pisciotta","year":"2021","journal-title":"Brain Sci"},{"issue":"17","key":"10.1016\/j.neurol.2022.11.006_bib0600","doi-asserted-by":"crossref","first-page":"e3278","DOI":"10.1097\/MD.0000000000003278","article-title":"Rehabilitation management of the Charcot-Marie-Tooth syndrome: a systematic review of the literature","volume":"95","author":"Corrado","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0605","first-page":"31","article-title":"Rehabilitation issues in Charcot-Marie-Tooth disease","volume":"9","author":"Kenis-Coskun","year":"2016","journal-title":"J Pediatr Rehabil Med"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0610","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/jns.12116","article-title":"Systematic review of exercise for Charcot-Marie-Tooth disease","volume":"20","author":"Sman","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"10.1016\/j.neurol.2022.11.006_bib0615","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.apmr.2003.12.025","article-title":"Resistance training effectiveness in patients with charcot-marie-tooth disease: recommendations for exercise prescription","volume":"85","author":"Chetlin","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0620","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mus.20078","article-title":"Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease","volume":"30","author":"Chetlin","year":"2004","journal-title":"Muscle and Nerve"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0625","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mus.20959","article-title":"Benefits of interval-training on fatigue and functional capacities in charcot-marie-tooth disease","volume":"37","author":"El Mhandi","year":"2008","journal-title":"Muscle and Nerve"},{"issue":"15","key":"10.1016\/j.neurol.2022.11.006_bib0630","first-page":"e1773","article-title":"Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity","volume":"9292","author":"Wallace","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.11.006_bib0635","first-page":"49","article-title":"Maladie de Charcot- Marie-Tooth \u00c9l\u00e9ments de r\u00e9\u00e9ducation fonctionnelle, kin\u00e9sith\u00e9rapie, ergoth\u00e9rapie","volume":"33","author":"Patrick Sautreuil","year":"2017","journal-title":"Med Sci"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0640","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5935\/1984-0063.20210025","article-title":"The impact of pain and nocturnal cramps on sleep quality in Charcot Marie Tooth disease: a case-control study","volume":"15","author":"Souza","year":"2022","journal-title":"Sleep Sci"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib0645","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jbmt.2019.10.014","article-title":"Massage therapy treatment and outcomes in a patient with Charcot-Marie-Tooth disease: a case report","volume":"24","author":"Paz","year":"2020","journal-title":"J Bodyw Mov Ther"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0650","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mus.27027","article-title":"Satisfaction with ankle foot orthoses in individuals with Charcot-Marie-Tooth disease","volume":"63","author":"Zuccarino","year":"2021","journal-title":"Muscle and Nerve"},{"issue":"8","key":"10.1016\/j.neurol.2022.11.006_bib0655","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PHM.0b013e31821f7172","article-title":"Assessment of appropriate ankle-foot orthoses models for patients with charcot-marie-tooth disease","volume":"90","author":"Guillebastre","year":"2011","journal-title":"Am J Phys Med Rehabil"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0660","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/17483107.2010.549899","article-title":"Ankle foot orthoses for people with Charcot Marie Tooth disease - Views of users and orthotists on important aspects of use","volume":"6","author":"Phillips","year":"2011","journal-title":"Disabil Rehabil Assist Technol"},{"issue":"17","key":"10.1016\/j.neurol.2022.11.006_bib0665","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1080\/09638288.2016.1211180","article-title":"A study of physical activity comparing people with Charcot-Marie-Tooth disease to normal control subjects","volume":"39","author":"Ramdharry","year":"2017","journal-title":"Disabil Rehabil"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0670","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pri.531","article-title":"Comparing Gait Performance of People with Charcot-Marie-Tooth Disease Who Do and Do Not Wear Ankle Foot Orthoses","volume":"17","author":"Ramdharry","year":"2012","journal-title":"Physiother Res Int"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0675","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0309364613506250","article-title":"An anterior ankle-foot orthosis improves walking economy in Charcot-Marie-Tooth type 1A patients","volume":"38","author":"Menotti","year":"2014","journal-title":"Prosthet Orthot Int"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0680","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.gaitpost.2013.07.121","article-title":"Functional and dynamic response characteristics of a custom composite ankle foot orthosis for Charcot-Marie-Tooth patients","volume":"39","author":"Dufek","year":"2014","journal-title":"Gait Posture"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib0685","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.25233","article-title":"One clinic's experience with carbon fiber orthoses in neuromuscular disease","volume":"55","author":"Ani Mnatsakanian","year":"2017","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0690","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive Immunosuppression in Progressive Multiple Sclerosis","volume":"308","author":"Hauser","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0695","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s10072-021-05646-9","article-title":"Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT","volume":"43","author":"Prada","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2022.11.006_bib0700","doi-asserted-by":"crossref","first-page":"105638","DOI":"10.1016\/j.clinbiomech.2022.105638","article-title":"Effects of orthopedic footwear on postural stability and walking in individuals with Hereditary Motor Sensory Neuropathy","volume":"94","author":"Lysanne de Jong","year":"2022","journal-title":"Clin Biomech"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0705","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/01.wnl.0000176062.44360.49","article-title":"Quality of life in patients with Charcot-Marie-Tooth disease","volume":"65","author":"Vinci","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0710","first-page":"27","article-title":"Poor compliance with ankle-foot-orthoses in Charcot-Marie-Tooth disease","volume":"44","author":"Vinci","year":"2008","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.neurol.2022.11.006_bib0715","series-title":"Modalit\u00e9s, indications, limites de la r\u00e9\u00e9ducation dans les pathologies neuromusculaires non acquises","author":"Anaes","year":"2001"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0720","first-page":"jrm00194","article-title":"Management of gait impairments in people with charcot-marie-tooth disease: A treatment algorithm","volume":"53","author":"Nonnekes","year":"2021","journal-title":"J Rehabil Med"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0725","first-page":"51","article-title":"Treatment for patients with Charcot-Marie-Tooth disease: Orthopaedic aspects","volume":"68","author":"Watanabe","year":"2016","journal-title":"Brain and Nerve"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib0730","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mus.25724","article-title":"Prevalence and orthopedic management of foot and ankle deformities in Charcot-Marie-Tooth disease","volume":"57","author":"Laur\u00e1","year":"2018","journal-title":"Muscle and Nerve"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0735","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01241398-198210000-00003","article-title":"Posterior tibial tendon transfer: A review of the literature and analysis of 74 procedures","volume":"2","author":"Miller","year":"1982","journal-title":"J Pediatr Orthop"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0740","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cpm.2015.06.004","article-title":"Jones Tendon Transfer","volume":"33","author":"Derner","year":"2016","journal-title":"Clin Podiatr Med Surg"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0745","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2106\/00004623-198062050-00004","article-title":"Tarsometatarsal truncated-wedge arthrodesis for pes cavus and equinovarus deformity of the fore part of the foot","volume":"62","author":"Jahss","year":"1980","journal-title":"J Bone Jt Surg - Ser A"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0750","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1302\/2058-5241.2.160077","article-title":"The adult cavus foot","volume":"2","author":"Maynou","year":"2017","journal-title":"EFORT Open Rev"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0755","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.fcl.2013.08.001","article-title":"What is the role and limit of calcaneal osteotomy in the cavovarus foot?","volume":"18","author":"Bariteau","year":"2013","journal-title":"Foot Ankle Clin"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0760","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2106\/00004623-200206000-00010","article-title":"Isolated gastrocnemius tightness","volume":"84","author":"DiGiovanni","year":"2002","journal-title":"J Bone Jt Surg"},{"issue":"12","key":"10.1016\/j.neurol.2022.11.006_bib0765","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3113\/FAI.2010.1057","article-title":"Surgical management and treatment algorithm for the subtle cavovarus foot","volume":"2010","author":"Maskill","year":"2010","journal-title":"Foot Ankle Int"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0770","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.fcl.2014.08.007","article-title":"Surgical techniques of gastrocnemius lengthening","volume":"19","author":"Hsu","year":"2014","journal-title":"Foot Ankle Clin"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0775","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.2106\/JBJS.N.00794","article-title":"Surgical treatment of cavus foot in Charcot-Marie-Tooth disease: A review of twenty-four cases: AAOS exhibit selection","volume":"97","author":"Faldini","year":"2015","journal-title":"J Bone Jt Surg - Am Vol"},{"issue":"12","key":"10.1016\/j.neurol.2022.11.006_bib0780","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2106\/JBJS.G.01356","article-title":"Long-term results of reconstruction for treatment of a flexible cavovarus foot in Charcot-Marie-Tooth disease","volume":"90","author":"Ward","year":"2008","journal-title":"J Bone Jt Surg"},{"issue":"3","key":"10.1016\/j.neurol.2022.11.006_bib0785","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.fas.2009.10.002","article-title":"Flexible cavovarus feet in Charcot-Marie-Tooth disease treated with first ray proximal dorsiflexion osteotomy combined with soft tissue surgery: A short-term to mid-term outcome study","volume":"16","author":"Leeuwesteijn AEEPM","year":"2010","journal-title":"Foot Ankle Surg"},{"issue":"7","key":"10.1016\/j.neurol.2022.11.006_bib0790","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/1071100720922220","article-title":"A Consensus Statement on the Surgical Treatment of Charcot-Marie-Tooth Disease","volume":"41","author":"Pfeffer","year":"2020","journal-title":"Foot Ankle Int"},{"issue":"3","key":"10.1016\/j.neurol.2022.11.006_bib0795","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jns.12404","article-title":"Long-term walking ability and patient satisfaction after lower limb functional surgery in patients affected by Charcot-Marie-Tooth disease: A retrospective study","volume":"25","author":"Carantini","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"22","key":"10.1016\/j.neurol.2022.11.006_bib0800","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1097\/BRS.0b013e3181573d4e","article-title":"Spinal deformities in hereditary motor and sensory neuropathy: A retrospective qualitative, quantitative, genotypical, and familial analysis of 175 patients","volume":"32","author":"Horacek","year":"2007","journal-title":"Spine (PhilaPa 1976)"},{"issue":"7","key":"10.1016\/j.neurol.2022.11.006_bib0805","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2106\/00004623-200707000-00014","article-title":"Scoliosis in patients with Charcot-Marie-tooth disease","volume":"89","author":"Karol","year":"2007","journal-title":"J Bone Jt Surg"},{"key":"10.1016\/j.neurol.2022.11.006_bib0810","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00003086-199906000-00008","article-title":"The periacetabular osteotomy: minimum 2 year followup in more than 100 hips","volume":"363","author":"Trumble","year":"1999","journal-title":"Clin Orthop Relat Res"},{"issue":"8","key":"10.1016\/j.neurol.2022.11.006_bib0815","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/BPO.0000000000000573","article-title":"Periacetabular osteotomy redirects the acetabulum and improves pain in charcot-marie-tooth hip dysplasia with higher complications compared with developmental dysplasia of the hip","volume":"36","author":"Novais","year":"2016","journal-title":"J Pediatr Orthop"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0820","first-page":"929","article-title":"Neuropathic pain in Charcot-Marie-Tooth disease: a clinical and laser-evoked potential study","volume":"26","author":"Peretti","year":"2022","journal-title":"Eur J Pain (United Kingdom)"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0825","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/WCO.0000000000000980","article-title":"Advances in the treatment of neuropathic pain","volume":"34","author":"Attal","year":"2021","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0830","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-020-05085-9","article-title":"Diabetic neuropathy: what does the future hold?","volume":"63","author":"Callaghan","year":"2020","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.neurol.2022.11.006_bib0835","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0003-9993(98)90421-X","article-title":"Neuropathic pain in Charcot-Marie-Tooth disease","volume":"79","author":"Gregory Carter","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"10.1016\/j.neurol.2022.11.006_bib0840","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.nmd.2014.06.433","article-title":"Quality-of-life in Charcot-Marie-Tooth disease: The patient's perspective","volume":"24","author":"Johnson","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0845","first-page":"109","article-title":"Current concepts in muscle stretching for exercise and rehabilitation","volume":"7","author":"Page","year":"2012","journal-title":"Int J Sports Phys Ther"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0850","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1212\/WNL.52.5.1064","article-title":"Charcot-Marie-Tooth disease type 2 with restless legs syndrome","volume":"52","author":"Gemignani","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.11.006_bib0855","unstructured":"French Healthcare Authority. National Diagnostic and Care Protocole for Charcot-Marie-Tooth disease 2021; https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-03\/pnds-cmt-sa-v2-converti.pdf."},{"issue":"12","key":"10.1016\/j.neurol.2022.11.006_bib0860","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1474-4422(09)70260-1","article-title":"Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Micallef","year":"2009","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib0865","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","article-title":"Ascorbic acid in charcot-marie-tooth disease type 1A (CMTTRIAAL and CMT-TRAUK): A double-blind randomised trial","volume":"10","author":"Pareyson","year":"2011","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2022.11.006_bib0870","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaneurol.2013.3178","article-title":"High-dosage ascorbic acid treatment in charcot-marie-tooth disease type 1A results of a randomized, double-masked, controlled trial","volume":"70","author":"Lewis","year":"2013","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0875","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","article-title":"A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A","volume":"16","author":"Attarian","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurol.2022.11.006_bib0880","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","article-title":"An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A","volume":"9","author":"Attarian","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0885","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1212\/01.WNL.0000171978.70849.c5","article-title":"NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients","volume":"65","author":"Sahenk","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib0890","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41434-018-0009-8","article-title":"AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model","volume":"25","author":"Yalvac","year":"2018","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib0895","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1085-9489.2005.0010206.x","article-title":"History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation","volume":"10","author":"Dyck","year":"2005","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0900","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/mus.26113","article-title":"Locally acting ACE-083 increases muscle volume in healthy volunteers","volume":"57","author":"Glasser","year":"2018","journal-title":"Muscle and Nerve"},{"key":"10.1016\/j.neurol.2022.11.006_bib0905","doi-asserted-by":"crossref","unstructured":"Thomas FP, Brannagan TH 3rd, Butterfield RJ, Desai U, Habib AA, Herrmann DN, Eichinger KJ, Johnson-Cl NE, Karam C, Pestronk A, Quinn C, Shy ME, Statland JM, Subramony SH, Walk D, Stevens-Favorite K, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology. 2022;98(23):e2356\u201367","DOI":"10.1212\/WNL.0000000000200325"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib0910","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41588-020-0615-4","article-title":"Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes","volume":"52","author":"Cortese","year":"2020","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib0915","doi-asserted-by":"crossref","first-page":"e150078","DOI":"10.1126\/sciadv.1500078","article-title":"Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model","volume":"1","author":"Nizzardo","year":"2015","journal-title":"Sci Adv"},{"key":"10.1016\/j.neurol.2022.11.006_bib0920","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nbd.2017.01.006","article-title":"Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo","volume":"100","author":"Lee","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0925","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s42003-021-01839-2","article-title":"Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A","volume":"4","author":"Boutary","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0930","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41467-021-22593-3","article-title":"AAV2\/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A","volume":"12","author":"Gautier","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.neurol.2022.11.006_bib0935","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0940","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI96499","article-title":"PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.neurol.2022.11.006_bib0945","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1093\/hmg\/ddy191","article-title":"Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer","volume":"27","author":"Pantera","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0950","first-page":"130","article-title":"Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice","volume":"48","author":"Lee","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"34","key":"10.1016\/j.neurol.2022.11.006_bib0955","doi-asserted-by":"crossref","first-page":"23146","DOI":"10.1074\/jbc.M109.027128","article-title":"P2X7-mediated increased intracellular calcium causes functional derangement in schwann cells from rats with CMT1A neuropathy","volume":"284","author":"Nobbio","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib0960","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1868-7083-4-5","article-title":"Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors","volume":"4","author":"Delcuve","year":"2012","journal-title":"Clin Epigenetics"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0965","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1007\/s12035-022-02782-x","article-title":"HDAC3 Inhibition Stimulates Myelination in a CMT1A Mouse Model","volume":"59","author":"Prior","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"22","key":"10.1016\/j.neurol.2022.11.006_bib0970","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1111\/bph.15231","article-title":"A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A","volume":"177","author":"Ha","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10.1016\/j.neurol.2022.11.006_bib0975","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.3664","article-title":"Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A","volume":"20","author":"Fledrich","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0980","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/hmg\/ddy411","article-title":"Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model","volume":"28","author":"Scapin","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.neurol.2022.11.006_bib0985","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.3390\/ijms22116048","article-title":"Emerging therapies for charcot-marie-tooth inherited neuropathies","volume":"22","author":"Stavrou","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.neurol.2022.11.006_bib0990","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/glia.22796","article-title":"CSF-1-activated macrophages are target-directed and essential mediators of schwann cell dedifferentiation and dysfunction in Cx32-deficient mice","volume":"63","author":"Groh","year":"2015","journal-title":"Glia"},{"issue":"Pt 11","key":"10.1016\/j.neurol.2022.11.006_bib0995","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1093\/brain\/awv240","article-title":"Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice","volume":"138","author":"Klein","year":"2015","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib1000","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/acn3.543","article-title":"Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B","volume":"5","author":"Bai","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"42","key":"10.1016\/j.neurol.2022.11.006_bib1005","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1523\/JNEUROSCI.0957-20.2020","article-title":"Phosphorylation of eIF2a promotes schwann cell differentiation and myelination in CMT1B mice with activated UPR","volume":"40","author":"Scapin","year":"2020","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.neurol.2022.11.006_bib1010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuron.2007.12.021","article-title":"Ablation of the UPR-Mediator CHOP Restores Motor Function and Reduces Demyelination in Charcot-Marie-Tooth 1B Mice","volume":"57","author":"Pennuto","year":"2008","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neurol.2022.11.006_bib1015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1084\/jem.20122005","article-title":"Resetting translational homeostasis restores myelination in charcot-marie-tooth disease type 1B mice","volume":"210","author":"D\u2019Antonio","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib1020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.nbd.2005.10.010","article-title":"Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression","volume":"22","author":"Fortun","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.neurol.2022.11.006_bib1025","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ajpath.2017.10.021","article-title":"Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients","volume":"188","author":"Lee","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurol.2022.11.006_bib1030","unstructured":"Bai Y, La Marche M, Wang D, Mastrangelo R, Treins C, Guedat P, et al. Treatment of Arg98Cys MPZ Mice In Vitro and In Vivo with IFB088. In: In Proceedings of the PNS Annual Meeting; Genoa; Italy. 22\u201325 June 2019."},{"key":"10.1016\/j.neurol.2022.11.006_bib1035","article-title":"Targeting the programmed axon degeneration pathway as a potential therapeutic for Charcot-Marie-Tooth disease","volume":"127","author":"Moss","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2022.11.006_bib1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113281","article-title":"HDAC6 inhibition promotes \u03b1-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice","volume":"328","author":"Picci","year":"2020","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2022.11.006_bib1045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fnmol.2018.00227","article-title":"What's the Function of Connexin 32 in the Peripheral Nervous System?","volume":"11","author":"Bortolozzi","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurol.2022.11.006_bib1050","doi-asserted-by":"crossref","unstructured":"Kagiava A., Karaiskos C., Richter J., Tryfonos C., Lapathitis G., Sargiannidou I., et al. Intrathecal gene therapy in mouse models expressing CMT1X mutations. Hum Mol Genet 2018;27(8)1460-1473.","DOI":"10.1093\/hmg\/ddy056"},{"key":"10.1016\/j.neurol.2022.11.006_bib1055","doi-asserted-by":"crossref","unstructured":"Kagiava A., Karaiskos C., Richter J., Tryfonos C., Jennings M.J., Heslegrave A.J., et al. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Ther 2021;28(10)659-675.","DOI":"10.1038\/s41434-021-00250-0"},{"key":"10.1016\/j.neurol.2022.11.006_bib1060","doi-asserted-by":"crossref","first-page":"723023","DOI":"10.3389\/fcell.2021.723023","article-title":"Allele-Specific Gene Editing Rescues Pathology in a Human Model of Charcot-Marie-Tooth Disease Type 2E","volume":"9","author":"Feliciano","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.neurol.2022.11.006_bib1065","doi-asserted-by":"crossref","unstructured":"Spaulding E.L., Sleigh J.N., Morelli K.H., Pinter M.J., Burgess R.W., Seburn K.L. Synaptic deficits at neuromuscular junctions in two mouse models of charcot-marie-tooth type 2d. J Neurosci 2016;36(11)3254-3267.","DOI":"10.1523\/JNEUROSCI.1762-15.2016"},{"key":"10.1016\/j.neurol.2022.11.006_bib1070","doi-asserted-by":"crossref","unstructured":"Ozes B., Moss K., Myers M., Ridgley A., Chen L., Murrey D., et al. AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in GarsP278KY\/+ mice.Brain Commun 2021;3(4)fcab252","DOI":"10.1093\/braincomms\/fcab252"},{"issue":"2","key":"10.1016\/j.neurol.2022.11.006_bib1075","article-title":"HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell-Based Model of Charcot-Marie-Tooth Disease (Type 2D)","volume":"6","author":"Smith","year":"2022","journal-title":"Adv Biol"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib1080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ana.25500","article-title":"A multicenter retrospective study of charcot-marie-tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs)","volume":"86","author":"Pareyson","year":"2019","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.11.006_bib1085","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41467-020-16696-6","article-title":"Rab35-regulated lipid turnover by myotubularins represses mTORC1 activity and controls myelin growth","volume":"11","author":"Sawade","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.neurol.2022.11.006_bib1090","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.15252\/emmm.201606349","article-title":"Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination","volume":"8","author":"Bolino","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib1095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mus.25981","article-title":"Charcot-Marie-Tooth Disease type 4C: Novel mutations, clinical presentations, and diagnostic challenges","volume":"57","author":"Jerath","year":"2018","journal-title":"Muscle and Nerve"},{"issue":"5","key":"10.1016\/j.neurol.2022.11.006_bib1100","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/brain\/awz064","article-title":"Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy","volume":"142","author":"Schiza","year":"2019","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.neurol.2022.11.006_bib1105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137159","article-title":"AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model","volume":"131","author":"Presa","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.neurol.2022.11.006_bib1110","article-title":"Description of orthotic properties and effect evaluation of ankle-foot orthoses in non-spastic calf muscle weakness","volume":"52","author":"Waterval","year":"2020","journal-title":"J Rehabil Med"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722008451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:45:17Z","timestamp":1758519917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722008451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":111,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0035378722008451"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.11.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Charcot-Marie-Tooth neuropathies","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}